A股異動丨科創新源復牌一字漲停 擬6億元收購東創精密100%股權
格隆匯10月24日丨科創新源(300731.SZ)復牌一字漲停,報24.9元,成交498萬元,總市值31億元。科創新源昨日公佈稱,公司擬以發行股份及支付現金的方式購買寧花香等11名交易對方合計持有的深圳市東創精密技術有限公司100.00%的股權;同時,公司擬向包括公司實際控制人周東在內的不超過5名特定投資者非公開發行股份募集配套資金。此次交易基於預估值的標的資產交易作價暫定為6億元,其中以現金支付3億元,以發行股份方式支付3億元。以發行價格24.88元/股計算,此次發行股份數量為1205.7877萬股。以此次交易預估值及預計交易作價為參考,擬募集配套資金約3億元,用以支付此次交易的現金對價。其中,發行對象周東認購此次募集配套資金金額1億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.